EGFR and non-small cell lung carcinoma: Targeted therapies against various driver mutations including the epidermal growth factor receptor (EGFR) have improved outcome in NSCLC patients whose tumors harbor these genetic abnormalities, whereas platinum-based chemotherapy remains the treatment of choice for most patients with tumors without “druggable” targets [3–5].